SABCS: Adjuvant Bevacizumab Fails to Improve Invasive DFS for Triple-Negative Breast Cancer
Triple-negative breast cancer patients with primary invasive cancer did not benefit from adjuvant combination chemotherapy plus bevacizumab compared to chemotherapy alone.